Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis ...
Almirall, S.A. (ALM) a global pharmaceutical company dedicated to medical dermatology announced today that China’s National Medical Products Administration (NMPA) has approved Seysara® (sarecycline ...
Almirall’s Seysara receives China NMPA approval for treatment of moderate-to-severe acne: Barcelona, Spain Saturday, January 31, 2026, 11:00 Hrs [IST] Almirall, S.A, a global ph ...
Vietnam Investment Review on MSN
Ascletis Acne Drug Shows Positive Phase Three Results
HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study (NCT06248008) evaluating denifanstat ...
"T acne" is a problem for transmasc men, but transfeminine women get it, too.
In A Nutshell Dissolving microneedle patches embedded with microscopic bubbles deliver three acne medications simultaneously, ...
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic ...
Sagimet Biosciences (SGMT) stock dips as Chinese partner Ascletis (ASCLF) reports Phase 3 trial data for the U.S. firm's acne drug denifanstat (ASC40). Read more here.
Clinical Trials Arena on MSN
Ascletis reports positive results in Phase III denifanstat trial for acne
Denifanstat showed tolerability and a favourable safety profile and most TEAEs were mild or moderate.
The open-label Phase 3 trial evaluated the safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne over a 40-week period. Denifanstat is being developed by Ascletis for acne in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results